Asset Details
Do you wish to reserve the book?
Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy
Do you wish to request the book?
Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy
2025
Overview
The 2021 WHO glioma classification integrates molecular profiling, but outcome data for these patients are limited. We retrospectively analyzed 179 patients (median age 53) with WHO 2021-classified gliomas (grade 2: n = 45, grade 3: n = 51, grade 4: n = 83) treated with surgery and radio(chemo)therapy across four centers in Poland and France. Chemotherapy was administered to 74.9% of patients, with a median radiotherapy dose of 60 Gy (range 32.5–80 Gy). IDH1/2 mutations were identified in 55.3% and 1p/19q codeletion in 22.4%. Patients with IDH1/2 mutations had significantly longer progression-free survival (PFS, 7.7 vs. 1.0 years) and overall survival (OS, 8.2 vs. 2.5 years), both
p
< 0.01. 1p/19q codeletion was associated with prolonged PFS (7.7 vs. 1.6 years,
p
< 0.01). In grade 3 gliomas, chemotherapy improved PFS (6.8 vs. 3.6 years) and OS (6.9 vs. 3.9 years), both
p
< 0.01. Leukopenia grade 0–2 correlated with better PFS (3.6 vs. 1.2 years, p = 0.02) and OS (7.2 vs. 3.2 years,
p
= 0.04). Absolute lymphocyte count ≤ 1 × 10
3
/mm
3
predicted worse OS (5.3 vs. 8.7 years,
p
= 0.0043). CTV < 127 cm
3
predicted longer OS in grade 4 gliomas (3.2 vs. 1.7 years,
p
= 0.012). Our findings provide new real-world evidence on survival and prognostic factors in this population, for which contemporary RWE and OS/PFS data remain scarce.
